NCT00731601

Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Lotung Poh-Ai Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.

Detailed description

A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. In the past few years, adjuvant use of a high-dose proton pump inhibitor (PPI) after endoscopic therapy has been endorsed in some studies, two consensus statements and two meta-analysis. In our previous experience, we used omeprazole 160 mg /day infusion instead of 8 mg/h in these patients and obtained a good result . The objectives of this study are to assess the outcomes of two different regimens of high dose of intravenous pantoprazole after endoscopic therapy in patients with peptic ulcer bleeding.

Conditions

• Peptic Ulcer Hemorrhage

Interventions

Type	Name	Description
DRUG	pantoprazole	pantoprazole 40 mg/q6h IV infusion for three days
DRUG	pantoprazole	pantoprazole 8 mg/h IV infusion for three days

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-03-01
• Completion: 2009-04-01
• First posted: 2008-08-11
• Last updated: 2009-04-07

Locations

1 site across 1 country: Taiwan